Affimed's common shares are listed on the NASDAQ Capital Market under the symbol AFMD. Who is Affimed's transfer agent? American Stock Transfer and Trust ...
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024 ... Events. All. All. Scientific. Investors. 31May. ASCO Annual Meeting.
People also ask
What does Affimed NV do?
When did Affimed go public?
Find the latest Affimed N.V. (AFMD) annual income ... Investor Relations Intelligence. Featured ... Start browsing Stocks, Funds, ETFs and more asset classes. /.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, ...
See the company profile for Affimed N.V. (AFMD) ... Affimed N.V. (AFMD). Follow. 4.8800 -0.4700 (-8.79 ... Head of Investor Relations & Director of Investor ...
Mar 6, 2024 · ... Investor Relations website, https://www.affimed.com/investors/. About Affimed N.V.. Affimed (Nasdaq: AFMD) is a clinical-stage immuno ...
Find the latest institutional holdings data for Affimed N.V. (AFMD) including shareholders, ownership summaries, and holding activities at Nasdaq.com.
Rating
(4,975)
Affimed (AFMD) will release its next earnings report on May 21, 2024. In the ... investors and does not represent returns that any investor actually attained.
Apr 12, 2024 · Affimed N.V. (AFMD) Investor Presentation - Slideshow · SA TranscriptsMon, Feb. 21, 2022. Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2021 Results ...
In depth view into AFMD (Affimed) stock including ... Affimed NV (AFMD). 5.12 +0.13 (+2.61%) USD | NASDAQ ... Investor Relations URL, https://www.affimed.com ...